Wegovy Helps Patients With Heart Failure Avoid Heart Attack, Stroke

Wegovy (semaglutide) reduces major adverse cardiac events by 28% in heart failure patients, regardless of ejection fraction type, and also lowers heart disease-related and all-cause mortality.